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Objective: The product of the met protooncogene, Met, is a tyro-
sine kinase receptor for hepatocyte growth factor (HGF). This sig-
naling pathway has been shown to be important in a number of
normal as well as malignant cellular processes including prolifera-
tion, metastases, motility, morphogenesis, and angiogenesis. The
overexpression of Met has been reported in a number of sarcomas
including rhabdomyosarcoma. We were interested in elucidating
the role of Met overexpression in rhabdomyosarcoma.
Methods: In order to gain a better understanding of the role of
Met  overexpression  in  rhabdomyosarcoma,  we  attempted  to
inhibit the expression of Met by transfecting an embryonal rhab-
domyosarcoma cell line, RD4A, with a met antisense  construct
and a chimeric U1 small nuclear RNA ribozyme antisense con-
struct. The biologic consequence of orthotopic as well as tail vein
injections  of  stable  clones  obtained  using  these  constructs  was
studied in SCID/Beige mice.
Results: Using  the  ribozyme  construct,  we  were  successful  at
maintaining one stable clone with an approximately 70% decrease
in Met expression as compared to the mock transfected controls.
Similarly, one stable clone with a 50% decrease in Met protein
expression as compared to the mock transfected clone was isolated
from the met antisense transfectants. Several of the stable clones
with significant knock down of Met expression could not be prop-
agated. A preliminary in vivo experiment using the met ribozyme
clone and controls in SCID/Beige mice was conducted to assess
the  affects of down regulation of Met in the establishment  and
growth of tumor in the gastrocnemius muscle. No significant dif-
ference in time to tumor take or tumor growth was observed in this
small cohort of mice. When the same cell lines were injected via tail
vein, none of the mice that received the cell line transfected with
the met ribozyme construct developed tumor metastases. Based on
these preliminary observations, we expanded the cohort of mice
used in this experiment. In addition, we included the RD4a clone
transfected with the met antisense clone to make sure our observa-
tions were not due to clonal variability within our cell line. Fifty
days post tail vein injection, 7 of 10 mice injected with the mock
transfected ribozyme control cell lines had evidence of metastatic
disease whereas 0 of 10 mice injected with the met ribozyme knock
down clone had evidence of metastatic disease. Similarly, 6 of 10
mice injected with the mock transfected control had evidence of
tumor metastases  whereas 1  of 10 mice  injected with antisense
transfected clone had evidence of tumor metastases 43 days post
injection. Taking into consideration the sequential tail vein exper-
iments, 23 of 30 mice injected with tumor cells containing wild
type  Met  developed  metastases  and  1  of  25  mice  with  clones
expressing  decreased Met developed metastases.  Using  Fisher’s
exact t-test, this data is extremely significant with a p-value of less
than 0.0001.
Conclusion: These observations would suggest that Met plays a
role in the metastatic process in rhabdomyosarcoma and may serve
as an excellent target in the setting of minimal residual disease.